Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : RWTH Aachen University, represented by the Rector, himself represented by the CTC-A

Femme et Homme Max 99 ans
RWTH Aachen University, represented by the Rector, himself represented by the CTC-A MAJ Il y a 4 ans

RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial Ruxolitinib im Vergleich zur besten verfügbaren Therapie in Patienten mit Hoch-Risiko Polycythemia vera oder Hoch-Risiko Essentieller Thrombozythämie – Die RUXO-BEAT Studie The objective of the Ruxo-BEAT trial is to assess the feasibility, safety, and efficacy of administration of ruxolitinib vs. best available therapy in patients with high-risk PV or high-risk ET. Pri...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations